


GP1642  
Atty Dr. No. 0999.004  
2300-0999  
PATENT

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on January 18, 2000

RECEIVED

JAN 28 2000



Date: 1/18/00 Signature: Patricia K. Ammer

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

RING

Serial No.: 08/349,489

Art Unit: 1642

Filing Date: December 2, 1994

Examiner: Y. Eyler

Title: METHOD OF PROMOTING AN IMMUNE RESPONSE WITH A  
BISPECIFIC ANTIBODY

TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Enclosed is a Declaration Regarding Deposit of Biological Materials in the above-identified case.

The Commissioner is hereby authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 18-1648.

Respectfully submitted,

Date: Jan. 18, 2000

By: D. Pasternak  
Dahna S. Pasternak  
Registration No. 41,411  
Attorney for Applicants

CHIRON CORPORATION  
Intellectual Property - R440  
P.O. Box 8097  
Emeryville, CA 94662-8097  
Telephone: (510) 923-8406  
Facsimile: (510) 655-3542

#  
22  
16  
2500



Atty Dkt No. 0999.004  
2300-0999  
08/349,489  
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

RING

Serial No.: 08/349,489

Filing Date: December 2, 1994

Art Unit: 1642

Examiner: Y. Eyster

**RECEIVED**

JAN 28 2000

Title: METHOD OF PROMOTING AN IMMUNE RESPONSE WITH A  
BISPECIFIC ANTIBODY

**DECLARATION REGARDING DEPOSIT OF BIOLOGICAL MATERIALS**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

I, Kimberlin L. Morley, declare as follows:

1. My title at Chiron Corporation is Corporate Patent Counsel and in that capacity I am authorized to act on behalf of Chiron Corporation.
2. The above-referenced application was originally assigned to Chiron Corporation and that all rights in this application are held in the name of Chiron Corporation (see Assignment recorded at Reel 7345 and Frames 0681, recorded 26 January 1995).
3. Hybridomas 35E6 and 42H8 were deposited with the American Type Culture Collection (A.T.C.C.), 10801 University Boulevard, Manassas, VA 20110-2209, on December 6, 1994 and February 7, 1995 and were given A.T.C.C. Accession Nos. HB11769 and HB11830, respectively.

4. Chiron Corporation agrees that the A.T.C.C. may grant the United States Patent and Trademark Office access to the cell lines identified in paragraph 3 during the pendency of the above-identified Patent Application to those determined by the Commissioner to be entitled thereto under 37 CFR 1.14 and 35 USC 122.

5. All restrictions on the availability to the public of the cell lines identified in paragraph 3 above will be irrevocably removed upon the granting of any patent issuing on the above-identified Patent Application.

6. Chiron Corporation intends that the cell lines identified in paragraph 3 above will be maintained at the named depository for a period of at least five (5) years after the most recent request for the furnishing of a sample of the deposited cell lines was received by the depository and, in any case, for a period of at least thirty (30) years after the date of the deposit, or during the enforceable life of the patent, whichever is latest, and Chiron Corporation will replace the cell lines should the cell lines become non-viable.

7. If the hybridomas of paragraph 3 should die or be destroyed during the effective term of the deposit, such hybridomas shall be replaced with a culture of the same.

8. Chiron Corporation believes that the biological material deposited as per paragraph 3 hereinabove is identical to the biological material identified in the specification as filed.

9. I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Respectfully submitted,

CHIRON CORPORATION

Date: Jan 5, 2000

By: Kimberlin L. Morley  
Kimberlin L. Morley  
Corporate Patent Counsel  
Reg. No. 35,391